Retinalamin
Longevity & Cellular HealthAlso known as: Ретиналамин, Retinal Peptide Extract, Bovine Retina Extract
Mechanism
Retinalamin is an injectable peptide extract derived from bovine retinal tissue, approved in Russia for the treatment of various eye diseases. Unlike the oral supplement Visoluten, Retinalamin is a pharmaceutical-grade retinal extract administered by injection (parabulbar or intramuscular). It is used clinically for diabetic retinopathy, age-related macular degeneration, glaucoma-related retinal damage, and post-surgical eye recovery. Russian clinical data reports improved visual acuity and retinal function in treated patients.
Technical detail
Retinalamin is a lyophilized polypeptide complex (MW <10 kDa) extracted from bovine retinal tissue. Contains tissue-specific peptides, amino acids, and microelements with affinity for retinal cells. Proposed mechanisms: (1) Neurotrophic — supports photoreceptor and retinal ganglion cell survival via upregulation of BDNF and CNTF expression in retinal tissue; (2) Antioxidant — enhances retinal glutathione system and SOD activity, protecting against photooxidative damage; (3) Vascular — normalizes retinal microcirculation by modulating endothelin-1 and nitric oxide balance in retinal vasculature; (4) Anti-apoptotic — reduces caspase-3 activity in stressed retinal cells; (5) Metabolic — normalizes retinal phospholipid composition and visual cycle enzyme activity. Russian clinical studies: improved visual acuity, ERG parameters, and visual field indices in diabetic retinopathy and AMD patients (Khavinson et al., multiple publications). Administered as parabulbar (periocular) injection, 5mg daily for 10 days.
Effects
OPHTHALMOLOGIC: Primary target system. Retinalamin is the injectable form of retinal bioregulation — delivering bovine retinal peptide extract directly to the periocular region for maximum retinal bioavailability. Unlike oral Visoluten, Retinalamin bypasses GI absorption and reaches retinal tissue more efficiently via periocular (parabulbar) injection. Clinical applications in Russia: (1) Diabetic retinopathy — Russian clinical studies report improved visual acuity by 0.1-0.3 (decimal scale), improved electroretinogram (ERG) parameters (a-wave and b-wave amplitudes), and reduced macular edema; (2) Age-related macular degeneration (dry AMD) — stabilization of visual acuity and improved contrast sensitivity; (3) Open-angle glaucoma — improved retinal ganglion cell function as measured by pattern ERG; (4) Central retinal vein occlusion — improved visual recovery. Proposed mechanisms: upregulation of neurotrophic factors (BDNF, CNTF) in retinal tissue; enhanced antioxidant defense (SOD, glutathione peroxidase); normalized retinal microcirculation via endothelin-1/NO balance; reduced retinal cell apoptosis via caspase-3 inhibition; improved photoreceptor outer segment renewal dynamics. IMMUNE: Modulates retinal immune microenvironment — may reduce chronic low-grade inflammation that drives AMD and diabetic retinopathy. NEUROLOGICAL: Retina is CNS tissue — retinal ganglion cell neuroprotection parallels CNS neuroprotection. Improved visual function improves quality of life and reduces fall risk in elderly. Tier 3: Users report improved visual acuity (especially night vision and contrast sensitivity), reduced eye fatigue, and stabilized vision in early AMD/diabetic retinopathy.
Practitioner Guide
DOSING TIPS: Standard Russian protocol: 5mg IM or parabulbar injection daily for 10 days. Repeat courses every 3-6 months. Parabulbar injection technique: requires trained ophthalmologist or experienced practitioner; inject into the inferotemporal periocular space. IM injection (deltoid): alternative for non-ophthalmologists. Reconstitute lyophilized powder with 1mL sterile water or saline. ADMINISTRATION: Parabulbar route delivers peptides closest to retinal tissue via transcleral diffusion. IM route is systemic — lower retinal bioavailability but safer (no periocular injection risks). Some practitioners alternate: parabulbar for first 5 days, IM for next 5 days. SUPPLEMENT SYNERGIES: AREDS2 formula (lutein, zeaxanthin, vitamin C, E, zinc, copper) — gold-standard AMD support. Astaxanthin (6-12mg/day) — crosses blood-retina barrier. Omega-3 DHA (1000mg+/day) — critical for photoreceptor membrane composition. Visoluten (oral) between Retinalamin courses for maintenance. Cortexin (if combined with neurological concerns — some Russian protocols combine Retinalamin + Cortexin for neuro-ophthalmic conditions). CYCLING: 10-day courses repeated every 3-6 months (standard Russian protocol). CONTRAINDICATION NUANCES: Wet (neovascular) AMD requiring anti-VEGF therapy — Retinalamin is not a substitute; may be used alongside under ophthalmologist supervision. Periocular injection risks: orbital hemorrhage, globe perforation (rare, requires experienced practitioner). Active ocular infection — treat first. Patients with bovine protein allergy — derived from bovine tissue. STORAGE: Lyophilized — room temperature or refrigerate, protect from light. Reconstituted — use immediately (single-use vials). PATIENT EDUCATION: This is the injectable "big brother" of Visoluten — it delivers retinal peptides directly where they are needed. It is approved in Russia and used routinely by Russian ophthalmologists for diabetic retinopathy, AMD, and glaucoma. The injection itself is brief and done in-office. You may notice improved clarity and contrast within days, but full effects develop over the course and subsequent months. Continue AREDS2 vitamins, protect eyes from UV, and manage systemic conditions (diabetes, blood pressure) that affect the retina.
Research Summary
TIER 1 (Gold Standard): No Western peer-reviewed RCTs. Russian State Pharmacopoeia monograph (approved pharmaceutical). TIER 2 (Strong): Khavinson et al. — Multiple Russian clinical publications on Retinalamin for diabetic retinopathy and AMD (Russian ophthalmology journals, peer-reviewed). Reported outcomes: visual acuity improvement, ERG normalization, reduced macular thickness. Maxiomova & Neroev — Retinalamin in ophthalmology (Russian monograph with clinical data). Trofimova et al. — Retinalamin effects on retinal function in glaucoma. TIER 3 (Moderate): Post-marketing surveillance data from Russia (decades of clinical use). Practitioner reports from integrative ophthalmology clinics. Product monograph from Geropharm (Russian manufacturer). KEY FINDINGS: (1) Most well-studied Khavinson retinal product with extensive Russian clinical data. (2) Reported benefits across multiple retinal conditions (DR, AMD, glaucoma). (3) Parabulbar injection provides superior retinal delivery. (4) No Western clinical validation. GAPS: No Western RCTs. Published Russian data often lacks the methodological rigor of Western trials (small sample sizes, inconsistent controls). Long-term efficacy data limited. Bioequivalence of IM vs. parabulbar route not established.